Patient death leads Seattle Children’s to pause study of 2seventy bio’s CAR-T cell therapy
2seventy bio said its partner Seattle Children’s has paused a Phase I study of the biotech’s CAR-T cell therapy following a patient death.
The therapy …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
